Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $326.29 -7.27%
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Provision (benefit) for income taxes: 15.57M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- National Fuel Gas (NFG) Tops Q4 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
